Ironwood Pharmaceuticals
IRWD
152 hedge funds and large institutions have $1.76B invested in Ironwood Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 26 increasing their positions, 96 reducing their positions, and 32 closing their positions.
41% more call options, than puts
Call options by funds: $8.76M | Put options by funds: $6.2M
6% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 32
3% less funds holding
Funds holding: 156 → 152 (-4)
16% less capital invested
Capital invested by funds: $2.1B → $1.76B (-$332M)
16.13% less ownership
Funds ownership: 119.79% → 103.66% (-16%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
73% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$19M |
| 2 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$13.8M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$10.4M |
| 4 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$9.04M |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$7.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$56.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$25M |
| 5 |
BlackRock
New York
|
-$18.3M |
IRWD Hedge Fund Activity: Q2 2019 in Review
152 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2019, worth a combined $1.76B — down 16% from $2.1B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of IRWD and 30 opened new positions — a net loss of 2 holders — while 96 trimmed existing stakes and 26 added.
The largest buyer was UBS AM, adding an estimated $19M. The largest seller was Bridger Management, exiting entirely with an estimated $56.6M sold.
- 152 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2019, down from 156 in Q1 2019.
- Funds reported $1.76B of Ironwood Pharmaceuticals stock for Q2 2019, down 16% quarter-over-quarter.
- 30 funds opened new Ironwood Pharmaceuticals positions in Q2 2019 and 32 closed out, a net change of -2 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2019 was UBS AM, an estimated $19M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2019 was Bridger Management, an estimated $56.6M sold.
Based on aggregated 13F filings for Q2 2019.